Total Intravenous Anesthesia With Remifentanil-propofol Admixture

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

96 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-12

Study Completion Date

2014-04-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: Application of total intravenous anesthesia (TIVA) may be considered as unpractical when compared with inhalational anesthesia. Although it is mostly not recommended, mixing intravenous agents seems to be popular in clinical practice. The aim of the study was to investigate the possible clinical drawbacks of using remifentanil-propofol admixture (MIXTIVA) for TIVA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System

NCT02492282

Anesthesia, General Anesthesia, Intravenous

COMPLETED PHASE3

Use of a Remifentanil-propofol Mixture in Patients Undergoing Breast Cancer Surgery

NCT03817359

Anesthetics Remifentanil Propofol

COMPLETED NA

MAC vs TIVA Ambulatory Breast Augmentation

NCT03764267

Breast Diseases

COMPLETED PHASE3

Myocardial Injury in Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimens in OPCAB Surgery

NCT02499445

Ischemic Heart Disease

COMPLETED NA

Remifentanil on Hemodynamic Response to Anesthesia Induction

NCT02763098

Anesthesia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ASA I-II adult patients scheduled for elective thyroidectomy were randomly allocated into 3 groups (n= 32 for each) to have TIVA either with remifentanil and propofol infusions separately (control group, Group I) or with MIXTIVA infusion that had remifentanil/propofol proportion 2/1000 or 3/1000 (remifentanil concentration 20 µg/ml or 30 µg/ml in propofol 1%, Group II or Group III respectively).

This technique may be considered as a practical implementation for busy ambulatory surgery centers performing general anesthesia, but delayed recovery may be predicted with longer duration of surgery and anesthesia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Intravenous Anesthesia Propofol Remifentanil Bispectral Index Monitoring

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TIVA

TIVA either with remifentanil and propofol infusions separately

No interventions assigned to this group

MIXTIVA 2/1000

MIXTIVA infusion that had remifentanil/propofol proportion 2/1000

Remifentanil-Propofol admixture

Intervention Type COMBINATION_PRODUCT

MIXTIVA 3/1000

MIXTIVA infusion that had remifentanil/propofol proportion 3/1000

Remifentanil-Propofol admixture

Intervention Type COMBINATION_PRODUCT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Remifentanil-Propofol admixture

Intervention Type COMBINATION_PRODUCT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

American Society of Anesthesiologists (ASA) physical status I patients American Society of Anesthesiologists (ASA) physical status II patients

Exclusion Criteria

American Society of Anesthesiologists (ASA) physical status III patients or above patients A body mass index \>35 kg/m2 Pregnant patients Breast-feeding Menstruating women Patients who were not euthyroid Uncontrolled hypertension Hepatic, renal or cardiac insufficiency Alcohol, opioid or drug abuse Allergy or contraindication to any of the study drugs

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No